<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> develops in 5-20% of patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> and predisposes to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The value of endoscopic biopsy surveillance is questioned because most patients do not develop <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, observer variation in histological diagnosis makes validation of surveillance guidelines difficult because varying histological interpretations may lead to different estimated rates of progression </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, objective biomarkers need to be validated for use with histology to stratify patients according to their risk for progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We prospectively evaluated patients using a systematic endoscopic biopsy protocol with baseline histological and flow cytometric abnormalities as predictors and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> as the outcome </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Among patients with negative, indefinite, or low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, those with neither <z:mp ids='MP_0004024'>aneuploidy</z:mp> nor increased 4N fractions had a 0% 5-yr cumulative <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence compared with 28% for those with either <z:mp ids='MP_0004024'>aneuploidy</z:mp> or increased 4N </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with baseline increased 4N, <z:mp ids='MP_0004024'>aneuploidy</z:mp>, and high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> had 5-yr <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidences of 56%, 43%, and 59%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:mp ids='MP_0004024'>Aneuploidy</z:mp>, increased 4N, or HGD were detected at baseline in <z:hpo ids='HP_0000001'>all</z:hpo> 35 patients who developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> within 5 yr </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: A systematic baseline endoscopic biopsy protocol using histology and flow cytometry identifies subsets of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> at low and high risk for progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Patients whose baseline biopsies are negative, indefinite, or low-grade displasia without increased 4N or <z:mp ids='MP_0004024'>aneuploidy</z:mp> may have surveillance deferred for up to 5 yr </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with cytometric abnormalities merit more frequent surveillance, and management of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> can be individualized </plain></SENT>
</text></document>